Donated tissue could reveal how HHT blood vessel tangles form
NCT ID NCT07826845
First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
Researchers at University Hospital Essen are studying donated tissue from people with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessel tangles called telangiectasias. The study compares tissue with and without these malformations, using antibody staining and cell counts to look at immune and endothelial cells. The goal is to better understand the disease mechanism. Participants must be adults with a genetic diagnosis of HHT or at least three Curacao criteria.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could clarify how HHT malformations form and point future research toward treatments that target the underlying biology.
- What could go wrong
- This is a very small tissue study with no treatment or direct benefit for participants. It may not find clear differences, and any insights would still need years of follow-up research before they could help patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 5 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * positiv genetic testing for HHT and/ or at least three fulfilled Curacao Criteria * older than 18 years Exclusion Criteria: * missing inclusion criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hereditary hemorrhagic telangiectasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut für Anatomie und Klinik für HNO-Heilkunde, Universitätsklinik Essen
RECRUITINGEssen, North Rhine-Westphalia, 45147, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill to stop the bleeding? new hope for HHT nosebleeds
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Blood thinners in HHT: a risky balancing act under the microscope
- Can a transplant drug stop HHT nosebleeds? small study tests sirolimus
- New antibody aims to tame rare bleeding disorder
- New drug aims to stop nosebleeds in rare blood vessel disorder